Loading clinical trials...
Loading clinical trials...
A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
Conditions
Interventions
MM-310
Locations
5
United States
Honor Health
Scottsdale, Arizona, United States
University California San Francisco
San Francisco, California, United States
Mayo Clinic
Rochester, Minnesota, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Duke University
Durham, North Carolina, United States
Start Date
February 22, 2017
Primary Completion Date
June 1, 2018
Completion Date
December 1, 2018
Last Updated
February 27, 2018
NCT04570423
NCT06926283
NCT07177937
NCT05889195
NCT07489378
NCT07181681
Lead Sponsor
Merrimack Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions